<DOC>
	<DOCNO>NCT00959946</DOCNO>
	<brief_summary>This research study 2 part assess follow parameter combination study drug call bosutinib , drug call capecitabine : safety , well subject 's body handle study drug , preliminary anti-tumor activity treatment different type cancer part 1 , breast cancer part 2 . In part 1 , subject receive bosutinib capecitabine daily different dose level drug order determine high tolerate dose combination study treatment . In part 2 , subject receive bosutinib capecitabine high tolerate dose see well study treatment work treat breast cancer . In addition , genetic research testing ( research analyse involve gene gene product ) perform biological sample subject .</brief_summary>
	<brief_title>Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer</brief_title>
	<detailed_description>The study prematurely discontinue follow Part 1 evaluation , sponsor conclude translational biomarker analysis need well define breast tumor biomarkers predict sensitivity Src family kinase inhibitor . Thus Sponsor make determination stop study Part 1 communicate investigator 02Dec2010 . No subject enrol Part 2 study . The study terminate due safety reason .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Part 1 : Ages eligible study : 18 year old . Male female . Confirmed pathologic diagnosis advance breast cancer pancreatic cancer colorectal cancer cholangiocarcinoma glioblastoma curable available therapy , bosutinib plus capecitabine reasonable treatment option . Part 2 : Ages eligible study : 18 year old . Female . Confirmed pathologic diagnosis locally advance metastatic breast cancer , locoregional recurrent breast cancer amenable curative treatment surgery radiotherapy . Documented ER+ and/or PgR+/erbB2 ER/PgR/erbB2 tumor base upon recently analyze biopsy . Part 1 : Prior bosutinib , prior Src inhibitor . Prior chemotherapy capecitabine 5FU treatment metastatic disease allow unless patient stop therapy toxicity . Part 2 : Prior bosutinib , prior Src inhibitor prior chemotherapy capecitabine 5FU treatment metastatic disease . Prior chemotherapy capecitabine 5FU adjuvant chemotherapy within past 12 month . erbB2+ breast cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase 1/2</keyword>
	<keyword>2-part study</keyword>
	<keyword>bosutinib capecitabine</keyword>
</DOC>